Dr. Adolfo Favaretto
LIST of publications with IF
Total IF: 383.368 (2011 Journal of Citation Report Institute of Scientific Information)
Total H Index : 16 (Harzing’s index 2011)
JOURNAL
IF
Publications
#
Total
IF
Acta Hematologica
American Journal of Clinical Oncology
Annals of Hematology
Annals of Oncology
Anticancer Research
British Journal of Cancer
BMC Cancer
Cancer
Cancer Treatment Reviews
Clinical Lung Cancer
Critical Review Oncology/Hematology
Current Drug Targets
Drugs
European Journal of Cancer
European Journal of Cardiothoracic Surgery
Journal of Clinical Oncology
Journal of the National Cancer Institute
Journal of Thoracic Oncology
Lancet Oncology
Lung Cancer
Melanoma Research
Minerva Biotecnologica
Oncology (Williston Park)
Oncotarget
Seminars in Oncology
Thoracic Cardiovascular Surgeon
Tumori
0,894
2,552
2,866
7,384
1,713
5,042
3,333
5,201
6,024
2,038
4,637
3,848
4,633
5,061
2,674
18,038
14,336
4,473
25,117
3,392
2,518
0,374
0,933
6,636
4,327
0,925
0,922
1
2
1
7
2
3
1
5
1
1
2
2
1
2
4
6
2
3
1
9
1
1
1
1
1
1
3
0,894
5,104
2,866
51,688
3,426
15,126
3,333
26,005
6,024
2,038
9,274
7,696
4,633
10,122
10,696
108,228
28,672
13,419
25,117
30,528
2,518
0,374
0,933
6,636
4,327
0,925
2,766
65
383,368
List of PAPERS (Peer Reviewed Journals)
1.
Cisplatin, etoposide and Ifosfamide in non-small cell lung carcinoma: a phase II randomized study with
cisplatin and etoposide as the control arm.
Paccagnella A, FAVARETTO A, Brandes A, Ghiotto C, Fornasiero A, Volpi A, Pappagallo G, Festi G, Cipriani
A, Vinante O, Chiarion-Sileni V and Fiorentino MV.
Cancer 65: 2631-2634. 1990.
2.
Second and third responses to the same induction regimen in relapsing patients with multiple myeloma.
Paccagnella A, Chiarion-Sileni V, Soesan M, Baggio G, Bolzonella S, De Besi P, Casara D, Frizzarin M,
Salvagno L, FAVARETTO A, Fiorentino MV.
Cancer 68: 975-980. 1991
3.
Extramedullary plasmacytoma: clinical behaviour and response to treatment.
Soesan M, Paccagnella A, Chiarion-Sileni V, Salvagno L, Fornasiero A, Sotti G, Zorat P-L, FAVARETTO A,
Fiorentino MV.
Annals of Oncology 3: 51-57. 1992
4.
Epirubicin, methotrexate and bleomycin (EMB) in the management of recurrent squamous cell head and
neck cancer. A GSTTC randomized phase-II study.
Paccagnella A, Pappagallo G, Segati R, Zorat PL, Cavaniglia GC, Lunghi F, Migliorini V, Frattina A, Bianco
A, Chiarion-Sileni V, Aversa S, FAVARETTO A, Vinante O, Fiorentino MV.
European Journal of Cancer 29A: 704-708. 1993
5.
Bone marrow myeloid cell kinetics during treatment of small cell carcinoma of the lung with
chemotherapy not associated and associated with granulocyte-macrophage colony stimulating factor.
Riccardi A, Danova M, Paccagnella A, Giordano M, FAVARETTO A, Panozzo M, Ghiotto C, Comis S,
Fiorentino MV, Chieco-Bianchi L, Ascari E.
Annals of Hematology 66: 185-193. 1993
6.
GM-CSF increases dose intensity of chemotherapyin small cell lung cancer. Relationship between clinical
results, peripheral blood cell modifications and bone marrow kinetics.
Paccagnella A, FAVARETTO A, Riccardi A, Danova M, Ghiotto C, Giordano M, Pappagallo G, Comis S,
Panozzo M, Chieco-Bianchi L, Fiorentino MV.
Cancer 72: 697-706. 1993
7.
A pilot study of concomitant radiation and chemotherapy in patients with locally advanced head and
neck cancer.
Tomio L, Zorat PL, Paccagnella A, Segati R, Loreggian L, Lora O, Friso ML, Chiarion-Sileni V, FAVARETTO
A, Fede A, Andreoli C, Francini F, Sala O, Fiorentino M, Calzavara F.
American Journal of Clinical Oncology (CCT) 16: 264-267. 1993
8.
Prognostic significance of flow cytometric DNA ploidy in lung cancer.
Ronchetti E, Danova M, Riccardi A, Paccagnella A, FAVARETTO A, Fiocca R, Mazzini G.
Oncology (Life Science Advances) 12: 75-80. 1993
9.
Mitomycin-C, Vinblastine and Carboplatin regimen in patients with Nonsmall Cell Lung Carcinoma. A
phase-II trial.
Paccagnella A, FAVARETTO A, Oniga F, Festi G, Lauro S, Morabito, A, Ossana L, Sartore F, DePoli F,
Fiorentino MV.
Cancer 78: 1701-1707. 1996
10.
Preoperative chemo-radiotherapy in non-small cell lung cancer stage-III patients. Feasibility, toxicity and
long-term results of a phase II study.
FAVARETTO A, Paccagnella A, Tomio L, Sartori F, Cipriani A, Zuin R, Reffosco L, Calabrò F, Rea F, Ghiotto
C, Chiarion-Sileni V, Oniga F, Loreggian L, Fiorentino MV.
European Journal of Cancer 32A: 2064-2069. 1996
11.
Paclitaxel and Carboplatin: a phase I study in advanced Non-small Cell Lung Cancer.
Paccagnella A, FAVARETTO A, Oniga F, Ossana L.
Seminars in Oncology 23 (suppl 16): 76-79. 1996
12.
Ultrarapid high-dose course of prophylactic cranial irradiation in small-cell lung cancer. Evaluation of
late neurologic morbidity in 16 long-term survivors.
Tomio L, Romano M, Zanchin G, Carollo C, Amistà P, Loreggian L, Saladini G, Berti F, Pignataro M,
Paccagnella A, FAVARETTO A, Rea F, Calzavara F.
American Journal of Clinical Oncology (CCT) 21:84-90. 1998
13.
Long term results of surgery and chemotherapy in small cell lung cancer.
Rea F, Callegaro D, FAVARETTO A, Loy M, Paccagnella A, Fantoni U, Festi G, Sartori F.
European Journal of Cardio-thoracic Surgery 14: 398-402. 1998
14.
The Elderly Lung Cancer Vinorelbine Italian Study Group: Effects of Vinorelbine on quality of life and
survival of elderly patients with advanced non small cell lung cancer.
Journal of the National Cancer Institute 91: 66-72. 1999
15.
The Role of surgery in integrated therapies for non-small cell lung cancer.
Sartori F, L Bortolotti, M Michelon, F Colaut, Loy M, Rea F, FAVARETTO A.
Annals of Oncology 10(suppl 5): S73-76. 1999
16.
Carboplatin and gemcitabine chemotherapy for malignant pleural mesothelioma: a phase II study of the
GSTPV.
Aversa SML, FAVARETTO A.
Clinical Lung Cancer 1: 73-75. 1999
17.
Paclitaxel and Carboplatin in combination with gemcitabine: a phase I-II trial in patients with advanced
Non-small Cell Lung Cancer.
FAVARETTO A, Ceresoli GL, Paccagnella A, Barbieri F, Bearz A, Ghiotto C, Oniga F, Schiavon S, Frustaci S,
Villa E.
Annals of Oncology 11: 1421-1426. 2000
18.
Phase-II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone
in advanced melanoma patients.
Chiarion-Sileni V, Nortilli R, Aversa S, Paccagnella A, Medici M, Corti L, FAVARETTO A, Cetto GL,
Monfardini S.
Melanoma Research 11: 189-196. 2001
19.
Neoadjuvant moderately high-dose chemotherapy with rh-G-CSF in locally advanced breast carcinoma.
Fornasiero A, Ghiotto C, Daniele O, FAVARETTO A, D’Amanzo P, Ziade A.
Tumori 87:223-228. 2001
20.
Elderly patients with small cell lung cancer.
Paccagnella A, Oniga F, FAVARETTO A, Biason R, Ghi MG.
Tumori 88(1 Suppl 1): S145-147. 2002
21.
Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian
Lung Cancer in the Elderly Study (MILES) phase III randomized trial.
Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, Barbera S, Ferrau F, Piazza E, Rosetti F,
Clerici M, Bertetto O, Robbiati SF, Frontini L, Sacco C, Castiglione F, FAVARETTO A, Novello S, Migliorino
MR, Gasparini G, Galetta D, Iaffaioli RV, Gebbia V; MILES Investigators.
Journal of the National Cancer Institute 95(5): 362-372. 2003
22.
Gemcitabine combined with Carboplatin in patients with malignant pleural mesothelioma. A
multicentric phase II study.
FAVARETTO A, Aversa SML, Paccagnella A, De Pangher Manzini V, Palmisano V, Oniga F, Stefani M, Rea
F, Bortolotti L, Loreggian L, Monfardini S.
Cancer 97: 2791-2797. 2003
23.
Supportive care in patients with advanced non-small-cell lung cancer.
Di Maio M, Perrone F, Gallo C, Iaffaioli RV, Manzione L, Piantedosi FV, Cigolari S, Illiano A, Barbera S,
Robbiati SF, Piazza E, Ianniello GP, Frontini L, Veltri E, Castiglione F, Rosetti F, De Maio E, Maione P,
Gridelli C, Rossi A, Barletta E, Barzelloni ML, Signoriello G, Bilancia D, Dinota A, Rosati G, Germano D,
Lamberti A, Pontillo V, Brancacio L, Crispino C, Esposito M, Battiloro C, Tufano G, Cioffi A, Guardasole V,
Angelini V, Guidetti G, Barbera S, Renda F, Romano F, Volpintesta A, Robbiati SF, Sannicolo M, Filipazzi V,
Esani G, Gambaro A, Ferrario S, Tinessa V, Caprio MG, Zonato S, Cabiddu M, Raina A, Veltri E, D'Aprile M,
Pistillucci G, Porcile G, Ostellino O, Vinante O, Azzarello G, Gebbia V, Borsellino N, Testa A, Gasparini G,
Morabito A, Gattuso D, Romito S, Carrozza F, Fava S, Calcagno A, Grimi E, Bertetto O, Ciuffreda L, Parello
G, Maiorino L, Santoro A, Santoro M, Failla G, Aiello RA, Bearz A, Sorio R, Scalone S, Clerici M, Bollina R,
Belloni P, Sacco C, Sibau A, Adamo V, Altavilla G, Scimone A, Spatafora M, Bellia V, Hopps MR,
Monfardini S, FAVARETTO A, Stefani M, Corradini GM, Pavia G, Scagliotti G, Novello S, Selvaggi G,
Tonato M, Darwish S, Michetti G, Belometti MO, Labianca R, Quadri A, De Marinis F, Migliorino MR,
Martelli O, Colucci G, Galetta D, Giotta F, Isa L, Candido P, Rossi N, Calandriello A, Ferrau F, Malaponte E,
Barni S, Cazzaniga M, Gebbia N, Valerio MR, Belli M, Colantuoni G, Capuano MA, Angiolillo M, Sollitto F,
Ardizzoia A, Luporini G, Locatelli MC, Pari F, Aitini E, Pedicini T, Febbraro A, Zollo C, Di Costanzo F,
Bartolucci R, Gasperoni S, Gaion F, Palazzolo G, Galligioni E, Caffo O, Cortesi E, D'Auria G, Curcio C, Vasta
M, Bumma C, Celano A, Bretti S, Nettis G, Anselmo A, Mattioli R, Nistico C, Aschelter A, Foa P.
British Journal of Cancer 89: 1013-21. 2003
24.
Cisplatin vs Carboplatin in combination with mitomycinand vinblastine in advanced Non-small Cell Lung
Cancer. A multicenter randomized phase-III trial.
Paccagnella A, FAVARETTO A, Oniga F, Barbieri F, Ceresoli G, Torri V Villa E, Verusio C, Cetto GL, Santo A,
De Pangher V, Artioli F, Cacciani G, Parodi G, Soresi E, Ghi MG, Morabito A, Biason R, Giusto M, Mosconi
C, Chiarion-Sileni V.
Lung Cancer 43: 83-91. 2004
25.
Long term survival and prognostic factors in thymic epithelial tumours.
Rea F, Marulli G, Girardi R, Bortolotti L, FAVARETTO A, Galligioni A, Sartori F.
European Journal of Cardio-thoracic Surgery 26: 412-418. 2004
26.
Stanford V Regimen plus Consolidative Radiotherapy Is an Effective Therapeutic Program for Bulky or
Advanced-Stage Hodgkin's Disease.
Aversa SM, Salvagno L, Soraru M, Mazzarotto R, Boso C, Gaion F, Chiarion-Sileni V, De Franchis G,
FAVARETTO AG, Crivellari G, Banna GL, Sotti G, Monfardini S.
Acta Haematologica 112(3): 141-147. 2004
27.
Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced
intensity conditioning regimens.
Banna GL, Aversa S, Chiarion-Sileni V, FAVARETTO A, Ghiotto C, Monfardini S.
Critical Review in Oncology Hematology. 51(3): 171-189. 2004
28.
Platinum-Etoposide chemotherapy in elderly patients with Small-Cell Lung Cancer: Results of a
randomized multicenter phase II study assessing attenuated-dose or full-dose with Lenograstim
prophylaxis—A Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori
Polmonari Veneto (FONICAP - GSTPV) Study.
Ardizzoni A, FAVARETTO A, Boni L, Baldini E, Castiglioni F, Antonelli P, Pari F, Ribaldi C, Altieri A, Barbera
S, Cacciani GC, Raimondi M, Tixi L, Stefani M, Monfardini S, Antilli A, Rosso R, Paccagnella A.
Journal of Clinical Oncology 23: 569-575. 2005
29.
Overview on ongoing or planned clinical trials in Europe.
FAVARETTO A.
Lung Cancer 49 (S1): S117—S121. 2005
30.
Pretreatment Quality of Life and Functional Status Assessment significantly predict survival of elderly
patients with Advanced Non–Small-Cell Lung Cancer Receiving Chemotherapy: A Prognostic Analysis of
the Multicenter Italian Lung Cancer in the Elderly Study
Maione P, Perrone F, Gallo C, Manzione L, Piantedosi F, Barbera S, Cigolari S, Rosetti F, Piazza E, Robbiati
S, Bertetto O, Novello S, Migliorino MR, FAVARETTO A, Spatafora M, Ferrau`F, Frontini L, Bearz A,
Repetto L, and Gridelli C.
Journal of Clinical Oncology 23: 6865-6872. 2005
31.
Adding Gemcitabine to Paclitaxel/Carboplatin Combination Increases Survival in Advanced Non-SmallCell Lung Cancer: Results of a Phase II-III Study
Paccagnella A, Oniga F, Bearz A, FAVARETTO A, Clerici M, Barbieri F, Riccardi A, Chella A, Tirelli U,
Ceresoli G, Tumolo S, Ridolfi R, Biason R, Belloni P, Nicoletto MO, Veglia F, and Ghi MG.
Journal of Clinical Oncology 24: 681-687. 2006
32.
Phase II study of Pemetrexed plus carboplatin in malignant pleural mesothelioma.
Ceresoli GL, Zucali PA, FAVARETTO A, Grossi F, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morenghi E,
Cavina R, Marangolo M, Soto Parra HJ, Santoro A.
Journal of Clinical Oncology 24: 1443-1448. 2006
33.
Non Platinum combination of gemcitabine in NSCLC.
FAVARETTO A.
Annals of Oncology 17 (Suppl 5): v82–v85. 2006
34.
The surgeon and the oncologist in Non Small Cell Lung Cancer (NSCLC).
Sartori F, Bortolotti L, Marulli G, Rizzardi G, FAVARETTO A, Zuin A, Breda C, Rea F.
Annals of Oncology 17 (Suppl 5): v94–v98. 2006
35.
Overprotective caregivers of elderly cancer patients: a case report.
Basso U, Brunello A, Magro C, FAVARETTO A, Monfardini S.
Tumori 92: 362-363. 2006
36.
Long-Term Results of Surgical Management of Pulmonary Metastases from Renal Cell Carcinoma.
Marulli G, Sartori F, Bassi PF, Dal Moro F, FAVARETTO AG, Rea F.
Thoracic Cardiovascular Surgeon 54: 544-547. 2006
37.
Single-Agent Pemetrexed or Sequential Pemetrexed/Gemcitabine as Front-Line Treatment of Advanced
Non-small Cell Lung Cancer in Elderly Patients or Patients Ineligible for Platinum-Based Chemotherapy: A
Multicenter, Randomized, Phase II Trial.
Gridelli C, Kaukel E, Gregorc V, Migliorino RM, Muller TR, Manegold C, FAVARETTO A, Martoni A, Caffo
O, Schmittel A, Rossi A, Russo F, Peterson P, Munoz M, Reck M.
Journal of Thoracic Oncology 2: 221-229. 2007
38.
Induction chemotherapy, extrapleural pneumonectomy and high dose hemithoracic irradiation in
malignant pleural mesothelioma.
Rea F, Marulli G, Bortolotti L, Breda C, FAVARETTO A, Loreggian L, Sartori F.
Lung Cancer 57: 89-95. 2007
39.
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in
advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study
Gridelli C, Gallo C, Cerebelli A, Gebbia V, Gamucci T, Ciardiello F, Carozza F, FAVARETTO A, Daniele B,
Galetta D, Barbera S, Rosetti F, Rossi A, Maione P, Cognetti F, Testa A, Di Maio M, Morabito A, Perrone F,
on behalf of the GECO investigators.
The Lancet Oncology 8: 500-512. 2007
40.
Cisplatin Plus Gemcitabine or Vinorelbine for Elderly Patients With Advanced Non–Small-Cell Lung
Cancer: The MILES-2P Studies.
Gridelli C, Maione P, Cerebelli Illiano A, Piantedosi FV, FAVARETTO A, Bearz A, Robbiati SF, Filippazzi V,
Lorusso V, Carozza F, Iaffaioli RV, Manzione L, Gallo C, Morabito A, Perrone F.
Journal of Clinical Oncology 25: 4663-4669. 2007
41.
Pemetrexed single agent in previously treated non-small cell lung cancer: A multi-institutional
observational study.
Bearz A, Garassino I, Cavina R, FAVARETTO A, Boccalon M, Salamini R, Berretta M, Spazzapan S,
Simonelli C, Santoro A, Tirelli U.
Lung Cancer 60: 240-245. 2008
42.
Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined
analysis of two phase II trials.
Ceresoli GL, Castagneto B, Zucali PA, FAVARETTO A, Mencoboni M, Grossi F, Cortinovis D, Del Conte G,
Ceribelli A, Bearz A, Salamina S, De Vincenzo F, Cappuzzo F, Marangolo M, Torri V, Santoro A.
British Journal of Cancer 99: 51-56. 2008
43.
Second and third line treatment in non-small cell lung cancer
FAVARETTO A, Pasello G, Magro C, Schettino C, Gridelli C.
Critical Review in Oncology Hematology 71: 117-126. 2009.
44.
Molecular Targets in Malignant Pleural Mesothelioma Treatment.
Pasello G, FAVARETTO A.
Current Drug Targets 10: 1235-1244. 2009
45.
Preoperative concomitant chemo-radiotherapy in superior sulcus tumour: A mono-institutional
experience.
FAVARETTO A, Pasello G, Loreggian L, Breda C, Braccioni F, Marulli G, Stragliotto S, Magro C, Sotti G, Rea
F.
Lung Cancer 68:228-233. 2010
46.
Effect of induction chemotherapy on lung function and exercise capacity in patients affected by
Malignant Pleural Mesothelioma.
Marulli G, Rea F, Nicotra S, FAVARETTO A, Perissinotto E, Chizzolini M, Vianello A, Braccioni F.
European Journal of cardio-thoracic surgery 37: 1464-1469. 2010
47.
Prognostic and Predictive Implications of EGFR Mutations, EGFR Copy Number and KRAS Mutations in
Advanced Stage Lung Adenocarcinoma.
Bonanno L, Schiavon M, Nardo G, Bertorelle R, Bonaldi L, Galligioni A, Indraccolo S, Pasello G, Rea F,
FAVARETTO A.
Anticancer Research 30: 5121-5128. 2010
48.
Multidisciplinary approach for advanced stage thymic tumors: long term outcome.
Rea F, Marulli G, Di Chiara F, Schiavon M, Perissinotto E, Breda C, FAVARETTO A, Calabrese F.
Lung Cancer 72: 68-72. 2011
49.
Italian Survey on Adjuvant treatment of non-small cell lung cancer (ISA)
Banna GL, Di Maio M, Collovà E, Menis J, Novello S, Bria E; ISA Co-Authors, Airoldi M, Amoroso D,
Ardizzoia A, Aurilio G, Bajetta E, Ballardini P, Barbieri F, Barletta E, Balzelloni ML, Basso U, Bernardini I,
Boni C, Bordin V, Bretti S, Bronte G, Brunetti C, Buti S, Capanna L, Colombo A, Condemi G, Cortinovis D,
Dambrosio M, Di Fonzo C, Di Lucca G, Dima G, Falzetta A, FAVARETTO A, Ferraù F, Garetto L, Gebbia V,
Genestreti G, Gentile AL, Giovanardi F, Labianca R, Lorusso V, Mantovani G, Martelli O, Massari F,
Mazzoli M, Michetti G, Mordenti P, Mucciarini C, Munao S, Nacci A, Pogliani C, Procopio G, Riccardi F,
Rizzato S, Rossi A, Rosti G, Russo P, Saladino T, Salesi N, Santangelo D, Sava T, Savarino A, Spinnato F,
Tiseo M, Tomassi O, Tondulli L, Tonini G, Turano S, Valerio MR, Verderame F, Zanelli F, Zanon E.
Lung Cancer 73: 78-88. 2011
50.
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non small
cell lung cancer: a randomized phase II study.
Gridelli C, Morgillo F, FAVARETTO A, De Marinis F, Chella A, Cerea G, Mattioli R, Tortora G, Rossi A,
Fasano M, Pasello G, Ricciardi S, MaioneP, Di Maio M, Ciardiello F.
Annals of Oncology 22: 1528-1534. 2011
51.
Mechanisms of acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and
New Therapeutic Perspectives in Non Small Cell Lung Cancer.
Bonanno L, Jirillo A, FAVARETTO A.
Current Drug Targets 12: 922-933. 2011
52.
Platinum-based doublet chemotherapy in pre-treated Malignant Pleural Mesothelioma (MPM) patients:
a mono-institutional experience.
Pasello G, Nicotra S, Marulli G, Rea F, Bonanno L, Carli P, Magro C, Jirillo A, FAVARETTO A.
Lung Cancer 73: 351-355. 2011
53.
Role of genotyping in non-small cell lung cancer treatment: current status.
Bonanno L, FAVARETTO A, Rugge M, Taron M, Rosell R.
Drugs 71: 2231-2246. 2011
54.
Molecular characterization into clinical practice: current status and future perspectives in metastatic
non-small cell lung cancer.
Bonanno L, Calvetti L, FAVARETTO A, Rosell R.
Minerva Biotecnologica 23: 103-116. 2011
55.
Phase I–II Trial of Gemcitabine-Based First-Line Chemotherapies for Small Cell Lung Cancer in Elderly
Patients with Performance Status 0–2. The G-Step Trial
Gridelli C, Gallo C, Morabito A, Iaffaioli RV, FAVARETTO A, Isa L, Barbera S, Gamucci T, Ceribelli A,
Filipazzi V, MaioneP, Rossi A, Barletta E, Signoriello S, De Maio E, Piccirillo MC, Di Maio M, Rocco G,
Vecchione A, Perrone F on behalf of the G-STEP Investigators.
Journal of Thoracic Oncology 7: 233-242. 2012
56.
Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in
clinical trials.
Di Maio M, Signoriello S, Morabito A, Rossi A, Maione P, Piantedosi FV, Bilancia D, Cigolari S, Barbera S,
Gebbia V, Daniele B, Robbiati SF, Illiano A, Ceribelli A, Carrozza F, FAVARETTO A, Piazza E, Piccirillo MC,
Daniele G, Giordano P, Costanzo R, Sandomenico C, Rocco G, Gallo C, Perrone F, Gridelli C.
Lung Cancer 76: 457-64. 2012
57.
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–
Small-Cell Lung Cancer: The TORCH Randomized Trial
Gridelli C, Ciardiello F, Gallo C, Feld R, Butts C, Gebbia V, Maione P, Morgillo F, Genestreti G,
FAVARETTO A, Leighl N, Wierzbicki R, Cinieri S, Alam Y, Siena S, Tortora G, Felletti R, Riccardi F, Mancuso
G, Rossi A, Cantile F, Tsao MS, Saieg M, da Cunha Santos G, Piccirillo MC, Di Maio M, Morabito A,
Perrone F.
Journal of Clinical Oncology 30: 3002-11. 2012
58.
Pemetrexed plus carboplatin or cisplatin as neoadjuvant treatment of operable malignant pleural
mesothelioma
Pasello G, Marulli G, Polo V, Breda C, Bonanno L, Loreggian L, Rea F, FAVARETTO AG.
Anticancer research 32: 5393-5400. 2012
59.
Quality of life of TORCH, a Randomized Trial testing First-Line Erlotinib Followed by Second-Line
Cisplatin/Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer.
Di Maio M, Leighl N, Gallo C, Feld R, Ciardiello F, Butts C, Maione P, Gebbia V, Morgillo F, Wierzbicki R,
FAVARETTO A, Alam Y, Cinieri S, Siena S, Bianco R, Riccardi F, Spatafora M, Ravaioli A, Felletti R, Fregoni
V, Genestreti G, Rossi A, Mancuso G, Fasano M, Morabito A, Tsao MS, Signoriello S, Perrone F, Gridelli C.
Journal of Thoracic Oncology 7: 1830-44. 2012
60.
An overview of neoadjuvant chemotherapy in the multimodality treatment of Malignant Pleural
Mesothelioma.
Pasello G, Ceresoli GL, FAVARETTO A.
Cancer Treatment Reviews 39: 10-7. 2013
61.
Changes in pulmonary function tests predict radiological response to chemotherapy in malignant pleural
mesothelioma
Marulli G, Di Chiara F, Braccioni F, Perissinotto E, Pasello G, Favaretto AG, Breda C, Rea F.
European Journal of cardio-thoracic surgery 44: 104-110. 2013
62.
Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the
treatment of pleural mesothelioma.
Rea F, FAVARETTO A, Marulli G, Spaggiari L, De Pas TM, Ceribelli A, Paccagnella A, Crivellari G, Russo F,
Ceccarelli M, Kazeem G, Marchi P, Facciolo F.
BMC Cancer 13:22. 2013
63.
The predictive value of BRCA1 and RAP80 mRNA expression in advanced non-small-cell lung cancer
patients treated with platinum-based chemotherapy.
Bonanno L, Costa C, Majem M, FAVARETTO A, Rugge M, Rosell R.
Annals of Oncology 24:1130-1132. 2013
64.
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural
mesothelioma.
Ceresoli G, Zucali P, Mencoboni M, Botta M, Grossi F, Cortinovis D, Zilembo N, Ripa C, Tiseo M,
FAVARETTO A, Soto Parra H, De Vincenzo F, Bruzzone A, Lorenzi E, Gianoncelli L, Ercoli B, Giordano L,
Santoro A
British Journal of cancer in press 2013 doi: 10.1038/bjc.2013.368. [Epub ahead of print]
65.
The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer
patients treated with first- line platinum-based chemotherapy.
Bonanno L, Costa C, Majem M, Sanchez JJ, Gimenez-Capitan A, Rodriguez I, Vergnenegre A, Massuti B,
FAVARETTO A, Rugge M, Pallares C, Taron M, Rosell R:
Oncotarget in press 2013
66.
Second and third line treatment in advanced non-small cell lung cancer.
FAVARETTO A, Pasello G:
Discovery Medicine 8 (43): 204-209. 2009
67.
Progetto ALTOP: algoritmo decisionale per il trattamento del paziente affetto da tumore
polmonare non a piccole cellule in stadio IIIb/IV
Grossi F, Gebbia V, Novello S, Aita M, Bidoli P, Di Costanzo F, FAVARETTO A, Ferraù F, Gregorc V,
Piantedosi F, Ricevuto E, Rinaldi M, Tagliaferri P, Ardizzoni A:
Tumori 96:1-24 2010
68.
A pathological complete response after preoperative chemotherapy with carboplatin and
pemetrexed in malignant pleural mesothelioma: A case report.
Pasello G, Altavilla G, Bonanno L, Rea F, FAVARETTO AG:
Journal of Thoracic Disease 2: 254-257. 2010
69.
Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience.
Bearz A, Talamini R, Rossoni G, Santo A, de Pangher V, Fasola G, Rosetti F, FAVARETTO A, Gregorc
V, Berretta M, Santarossa S, Berto E, Tirelli U:
BMC Research Notes 5:482. 2012
70.